ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

INOV Schroders Capital Global Innovation Trust Plc

11.35
-0.15 (-1.30%)
24 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Schroders Capital Global Innovation Trust Plc LSE:INOV London Ordinary Share GB00BVG1CF25 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.15 -1.30% 11.35 11.35 11.45 11.50 11.35 11.35 1,351,775 16:35:08
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Trust,ex Ed,religious,charty -31.19M -33.8M -0.0408 -2.82 95.23M

Schroders Capital Global Innovation Follow-on investment in iOnctura BV

20/06/2024 7:30am

RNS Regulatory News


RNS Number : 0799T
Schroders Capital Global Innovation
20 June 2024
 

20 June 2024

 

Schroders Capital Global Innovation Trust plc

Follow-on investment in iOnctura BV

 

Schroders Capital Global Innovation Trust plc (the "Company") is pleased to announce its second follow-on investment in iOnctura BV ("iOnctura"), a clinical-stage biotech firm that focuses on combating neglected and hard-to-treat cancers by developing experimental oral small molecule treatments designed to maximise anti-tumour efficacy while prioritising patient safety. The Company invested £1.4 million (EUR 1.7 million) in a funding round that raised £68 million (EUR 80 million). This round was led by new investor Syncona and saw participation from the European Innovation Council Fund and other existing investors including M Ventures, Inkef Capital, VI Partners, and 3B Future Health Fund.

 

In December 2023, iOnctura shared positive clinical data for roginolisib, an oral allosteric modulator of PI3Kδ used to treat various solid and hematologic malignancies, including uveal melanoma. The funding will be utilised to expedite the development of roginolisib for treating uveal melanoma (UM), a rare eye cancer. In the Phase Ib clinical trial, roginolisib showed long-term safety and promising efficacy in UM, demonstrating sustained clinical activity over many months. Comprehensive results will be released in the upcoming months.

 

Moreover, the Series B financing will be used to further develop iOnctura's pipeline asset, IOA-289 (cambritaxestat). Cambritaxestat is an autotaxin inhibitor in clinical development for cancer treatment. It is targeted towards highly fibrotic tumours that overexpress autotaxin. A Phase Ib study of cambritaxestat in combination with chemotherapy in metastatic pancreatic cancer is currently in progress.

 

This investment aligns with the Company's sub-strategy of backing innovative life science companies at the near-clinical or clinical stage of development. This investment follows the Company's initial £1.4 million (EUR 1.6 million) investment in iOnctura's previous £9.4 million (EUR 11.1 million) convertible loan note in Q3 2022. The Company's total investment in iOnctura now stands at £2.8 million (EUR 3.3 million).

 

Enquiries:

Schroder Investment Management Limited

Kirsty Preston (Press)                    0207 658 1961

John Spedding                                0207 658 3206


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRSFAFSUELSEDM

1 Year Schroders Capital Global... Chart

1 Year Schroders Capital Global... Chart

1 Month Schroders Capital Global... Chart

1 Month Schroders Capital Global... Chart

Your Recent History

Delayed Upgrade Clock